Reflection paper on the dissolution specification for ...
limited by solubility / intrinsic dissolution of the active substance, i.e. BCS II and IV, suitable quality attributes may be particle size of the active substance or other attr ibutes that would have an impact on the . in vivo. dissolution. For a finished product where the . in vivo.
Download Reflection paper on the dissolution specification for ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Solubility of CaSO4
alpha.chem.umb.eduthe calcium ions and sulfate ions come from the dissolution of CaSO 4, [Ca 2+] = [SO 4 2-]. In fact, the same statement can also be made for the second saturated solution, since KNO 3 is not a source of Ca ... solubility will be significantly larger than the 5.0 mM predicted above.
A review of polymer dissolution
wwwcourses.sens.buffalo.edusolubility behavior of polymers and their solvents, (3) models used to interpret and understand polymer dissolution, and (4) techniques used to characterize the dissolution process. q …
PROPOSAL TO WAIVE IN VIVO BIOEQUIVALENCE …
www.who.intThe API is not prone to precipitation after its dissolution due to its good solubility under all pH conditions likely to be found in the upper gastrointestinal tract. The high permeability assures the complete uptake (> 90%) of the API during its passage through the small intestine. The fast dissolution of the product
General Tests and Assays - USP-NF
www.uspnf.comFirst Supplement to USP 40–NF 35 Annotated List7987 PERFORMANCE TESTS ASSAY Dissolution and Uniformity of Dosage Units Procedure IMPURITIES IMPURITIES 4-Aminophenol in Acetaminophen-Containing Organic Impurities (added) Drug Products (added) ADDITIONAL REQUIREMENTS Acetohexamide (deleted), 8204 USP Reference Standards …